Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05215470

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer

Sponsor: Bristol-Myers Squibb

Conditions Renal Cancer Metastatic

Interventions Ipilimumab Nivolumab

Updated 6 times since 2022 Last updated: Jul 1, 2024 Started: Jan 18, 2022 Primary completion: Nov 30, 2024 Completion: Nov 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Cancer Metastatic and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Nov 2022 — Mar 2023 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Feb 2022 — Nov 2022 [monthly]

Recruiting PHASE2

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Fundação de Amparo à Pesquisa do Estado de São Paulo
Hospital das Clínicas de Ribeirão Preto

Data source: Hospital das Clínicas de Ribeirão Preto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ribeirão Preto, Brazil